Cited 13 times in
Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김송이 | - |
dc.contributor.author | 김영삼 | - |
dc.contributor.author | 박무석 | - |
dc.contributor.author | 이상훈 | - |
dc.contributor.author | 이은혜 | - |
dc.contributor.author | 임아영 | - |
dc.contributor.author | 장준 | - |
dc.contributor.author | 정경수 | - |
dc.contributor.author | 정지예 | - |
dc.contributor.author | 강영애 | - |
dc.date.accessioned | 2019-07-11T03:11:18Z | - |
dc.date.available | 2019-07-11T03:11:18Z | - |
dc.date.issued | 2019 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/169870 | - |
dc.description.abstract | Background: Treatment outcomes of multidrug-resistant tuberculosis (MDR TB) remain poor, particularly for fluoroquinolone-resistant (FQ-R) MDR TB. The aim of this study was to determine treatment outcomes and factors associated with failure of MDR TB treatment, focusing on FQ resistance. Methods: Medical records were retrospectively reviewed of patients diagnosed and treated for MDR TB from January 2005 through December 2017 at Severance Hospital, South Korea. Results: Of a total of 129 patients with MDR TB, 90 (69.8%) cases were FQ-sensitive (FQ-S) and 39 (30.2%) were FQ-R. FQ-R MDR TB was associated with more severe clinical symptoms, including cavitary lesions and bilateral disease, and tended to require treatment with a greater number of drugs for a longer period of time than FQ-S MDR TB. Linezolid (51.3% vs 7.8%, P < .001), bedaquiline (20.5% vs 8.9%, P = .083), and delamanid (10.3% vs 5.6%, P = .452) were more frequently used in FQ-R cases. Overall, 95/124 patients (76.6%) had favorable treatment outcomes, and we did not detect a significant difference between FQ-R and FQ-S (FQ-S 65/87, 74.7%, vs FQ-R 30/37, 81.1%; P = .443). Old age, low body mass index, smoking, and malignancy-but not FQ resistance or extensively drug-resistant (XDR) TB-were associated with poor clinical outcomes. Conclusions: Overall, 76.6% of MDR TB patients had successful treatment outcomes. Effective drug combinations and appropriate use of new drugs may improve treatment outcomes of FQ-R MDR and XDR TB. Poor clinical outcomes were more related to the patients' general condition rather than FQ resistance or XDR. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | OPEN FORUM INFECTIOUS DISEASES | - |
dc.publisher | OPEN FORUM INFECTIOUS DISEASES | - |
dc.relation.isPartOf | OPEN FORUM INFECTIOUS DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Eun Hye Lee | - |
dc.contributor.googleauthor | Seung Hyun Yong | - |
dc.contributor.googleauthor | Ah Young Leem | - |
dc.contributor.googleauthor | Sang Hoon Lee | - |
dc.contributor.googleauthor | Song Yee Kim | - |
dc.contributor.googleauthor | Kyung Soo Chung | - |
dc.contributor.googleauthor | Ji Ye Jung | - |
dc.contributor.googleauthor | Moo Suk Park | - |
dc.contributor.googleauthor | Young Sam Kim | - |
dc.contributor.googleauthor | Joon Chang | - |
dc.contributor.googleauthor | Young Ae Kang | - |
dc.identifier.doi | 10.1093/ofid/ofz118 | - |
dc.contributor.localId | A00626 | - |
dc.contributor.localId | A00707 | - |
dc.contributor.localId | A01457 | - |
dc.contributor.localId | A02836 | - |
dc.contributor.localId | A03053 | - |
dc.contributor.localId | A03382 | - |
dc.contributor.localId | A03472 | - |
dc.contributor.localId | A03570 | - |
dc.contributor.localId | A03735 | - |
dc.contributor.localId | A00057 | - |
dc.relation.journalcode | J03621 | - |
dc.identifier.eissn | 2328-8957 | - |
dc.identifier.pmid | 30949546 | - |
dc.subject.keyword | MDR TB | - |
dc.subject.keyword | XDR TB | - |
dc.subject.keyword | fluoroquinolone resistance | - |
dc.subject.keyword | treatment outcomes | - |
dc.contributor.alternativeName | Kim, Song Yee | - |
dc.contributor.affiliatedAuthor | 김송이 | - |
dc.contributor.affiliatedAuthor | 김영삼 | - |
dc.contributor.affiliatedAuthor | 박무석 | - |
dc.contributor.affiliatedAuthor | 이상훈 | - |
dc.contributor.affiliatedAuthor | 이은혜 | - |
dc.contributor.affiliatedAuthor | 임아영 | - |
dc.contributor.affiliatedAuthor | 장준 | - |
dc.contributor.affiliatedAuthor | 정경수 | - |
dc.contributor.affiliatedAuthor | 정지예 | - |
dc.contributor.affiliatedAuthor | 강영애 | - |
dc.citation.volume | 6 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | ofz118 | - |
dc.identifier.bibliographicCitation | OPEN FORUM INFECTIOUS DISEASES, Vol.6(4) : ofz118, 2019 | - |
dc.identifier.rimsid | 62243 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.